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Abstract
The Netherlands Study of Depression and Anxiety (NESDA) is a multi-site naturalistic cohort study to: (1) describe the 
long-term course and consequences of depressive and anxiety disorders, and (2) to integrate biological and psychosocial 
research paradigms within an epidemiological approach in order to examine (interaction between) predictors of the long-
term course and consequences.
Its design is an eight-year longitudinal cohort study among 2981 participants aged 18 through 65 years. The sample 
consists of 1701 persons with a current (six-month recency) diagnosis of depression and/or anxiety disorder, 907 persons 
with life-time diagnoses or at risk because of a family history or subthreshold depressive or anxiety symptoms, and 373 
healthy controls. Recruitment took place in the general population, in general practices (through a three-stage screening 
procedure), and in mental health organizations in order to recruit persons refl ecting various settings and developmental 
stages of psychopathology. During a four-hour baseline assessment including written questionnaires, interviews, a medical 
examination, a cognitive computer task and collection of blood and saliva samples, extensive information was gathered 
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about key (mental) health outcomes and demographic, psychosocial, clinical, biological and genetic determinants. Detailed 
assessments will be repeated after one, two, four and eight years of follow-up.
The fi ndings of NESDA are expected to provide more detailed insight into (predictors of) the long-term course of 
depressive and anxiety disorders in adults. Besides its scientifi c relevance, this may contribute to more effective prevention 
and treatment of depressive and anxiety disorders. Copyright © 2008 John Wiley & Sons, Ltd.
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Introduction
Depressive and anxiety disorders are common at all 
ages. In addition, their effects on well-being and daily 
functioning are enormous and comparable to those of 
major chronic physical illnesses (Buist-Bouwman et al., 
2006; Murray and Lopex, 1997). In economic terms, 
the cost of depressive and anxiety disorders due to loss 
of productivity and use of health services ranks among 
the top-fi ve of all disorders (Smit et al., 2006). Conse-
quently, depressive and anxiety disorders are relevant 
candidates for efforts to improve public health.
During the past decades, progress has been made in 
the development and testing of different forms of treat-
ment for depressive and anxiety disorders. Although 
successful treatment is available, a large proportion of 
those affected remains undiagnosed and untreated (Bijl 
and Ravelli, 2000), and treatment is not effective for 
everyone. Moreover, although it is fi rmly established 
that the duration of episodes can be infl uenced with 
treatment, it is uncertain whether treatment has effect 
on the long-term course of depressive or anxiety disor-
ders. The extremely variable natural history precludes 
matching interventions accurately to those who are 
most in need of treatment. This is refl ected in current 
professional treatment guidelines which offer little 
guidance as to which patients may recover without 
substantial treatment and which patients may be in 
need of more intensive interventions. A fi rst require-
ment for a more accurate matching of limited treatment 
resources to the projected need of patients is to have 
detailed knowledge of the factors that determine or 
predict the prognosis. For this, data on (determinants 
of) the long-term course and consequences of anxiety 
and depressive disorders are essential.
We are currently conducting the Netherlands Study 
of Depression and Anxiety (NESDA), a multi-centre 
study designed to examine the long-term course and 
consequences of depressive and anxiety disorders. This 
paper presents the basic rationales, objectives and 
methods of NESDA.
Key rationales
There were four key rationales that guided our design, 
which will be discussed.
Rationale 1: Insight into long-term prognosis of depressive 
and anxiety disorders is limited
Both in the literature and in clinical practice, the 
disease-episode-model for the prognosis of depression 
and anxiety dominates. Using this model, the median 
duration of episodes of major depressive disorder (MDD) 
ranges between 3–6 months, whereas using the prevail-
ing defi nition of chronicity of MDD (duration > two 
years) approximately 20% of episodes becomes chronic 
(Keller et al., 1992; Spijker et al., 2002). Nevertheless, 
although remission occurs, the course of MDD is typi-
fi ed by recurrences: in a meta-analysis of studies among 
depressed patients in psychiatric settings, 76% had one 
or more recurrent episodes over 10 years (Piccinelli and 
Wilkinson, 1994). Although several studies of the prog-
nosis of MDD are available, the Collaborative Depres-
sion Study (CDS) has probably been the most infl uential. 
In this study, 431 adults with MDD who were treated 
in academic centres were followed over 12 years. Using 
the disease-episode-model, the above fi gures for dura-
tion of episodes were reached (Keller et al., 1992; Keller 
at al., 1984). However, using the life-chart method the 
prognosis appeared to be pleiomorphic with symptom 
levels changing frequently; patients were symptomati-
cally ill in 59% of the weeks over 12 years, much of 
which at the minor, dysthymic or subthreshold level 
(Judd et al., 1998). Using similar methodology in popu-
lation-based studies provided rather similar conclusions 
indicating that depression is a chronic intermittent dis-
order in the majority of cases (Judd, 1997). Therefore, 
to describe the longitudinal course, the disease-episode-
model for the prognosis of affective disorders should be 
complemented with a dimensional model describing 
the waxing and waning of symptoms (Duncan-Jones 
et al., 1990).
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For anxiety disorders, the (few) studies examining 
the course, have also focused on the disease-episode 
model. The Harvard/Brown Anxiety Research pro-
gramme (HARP) repeatedly assessed 711 psychiatric 
outpatients with anxiety disorder (panic, social phobia 
or generalized anxiety disorder) at 6 to 12 month inter-
vals over 10 years. The course of anxiety disorders 
appeared to be poor with the smallest probability of 
recovery for social phobia (Bruce et al., 2005). Only 
35% of 232 outpatients with social phobia recovered 
during 10 years, whereas the recurrence rate once 
recovery was achieved was 34% (Keller, 2006). In two 
reviews, it was estimated that the course of panic dis-
order shows only little to no improvement in 36–40% 
of the subjects after 1 to 20 years of treatment (Keller 
and Hanks, 1993; Pollack and Otto, 1997). These results 
depict anxiety disorders as insidious with low recovery 
rates and high recurrence rates, and beg for more natu-
ralistic long-term studies that examine episodes as well 
as symptoms in order to improve our knowledge about 
the course of anxiety disorders.
Rationale 2: When studying depression and anxiety 
disorders, different settings and developmental stages 
should be considered
Although common throughout settings, the prevalence 
of depressive and anxiety disorders increases as one 
moves from the community, through primary care, to 
specialized health care settings (Goldberg and Huxley, 
1992). Those with the most severe, complex, recurrent 
and longstanding disorders are more likely to be referred 
to specialized mental health care (Bijl and Ravelli, 
2000). The setting in which subjects are recruited is 
therefore crucial to the outcome, since those recruited 
in specialized mental health care are a selection of 
those with the least favourable prognosis. Unfortu-
nately, there are no longitudinal studies that have 
included suffi cient subjects representative of those suf-
fering from depressive and anxiety disorders in different 
health care settings. Studies like HARP and CDS (dis-
cussed earlier) provide information on the course of 
psychiatric outpatients in specialty clinics, but the 
extent to which this information is generalizable to 
community and primary care settings – where the 
majority of cases resides – needs to be determined.
The clinical developmental stage of a disorder has 
shown to be a key determinant of the course of a 
depressive or anxiety disorder. This can be best 
demonstrated by the importance of previous history, 
duration and severity of the index episode for the prog-
nosis (Spijker et al., 2002). However, these clinical 
factors do not explain the wide variation in the prog-
nosis: it is highly likely that underlying biological and 
psychosocial factors, such as genetics or personality, 
partly determine both the clinical features of index 
episodes and its subsequent course. Patients enrolled in 
specialized health care settings generally have a more 
progressed developmental stage of their illness than 
patients in primary care or community settings (Suh 
and Gallo, 1997; Cooper-Patrick et al., 1994). Conse-
quently, clinical setting and developmental stage of the 
illness are highly correlated. To obtain a full under-
standing of the course of depressive and anxiety disor-
ders, it is crucial to design studies that include patients 
from different settings and developmental stages of 
illness. Such a study would not only allow comparison 
of the (prediction of) course between patients from 
different settings and developmental stages, but would 
also allow for studies of trajectories of care, focusing on 
factors determining transitions from informal to differ-
ent levels of formal care.
Rationale 3: Depressive and anxiety disorders should be 
studied in concert
Previous studies have shown that comorbidity among 
depressive and anxiety disorders is rule rather than 
exception: comorbidity rates range from 30% through 
60% (Kessler et al., 1994; Beekman et al., 2000; Angst, 
1996; Sartorius et al., 1996; van Balkom et al., 2000; 
de Graaf et al., 2002). Depressive and anxiety disorders 
often arise sequentially within the same patient: the 
order is more likely to start with anxiety, depression 
commonly arising later (Merikangas et al., 1996; 
de Graaf et al., 2002). Another line of research shows 
that patients with both anxiety and depression have 
more severe symptoms, more disability, a longer dura-
tion of illness and are less likely to respond to treatment 
(Vollrath and Angst, 1989; Bijl and Ravelli, 2000; 
Hecht and Wittchen, 1990; Roy-Byrne et al., 2000; 
Bruce et al., 2005; Ormel et al., 1994). Finally, analyses 
of depression and anxiety comorbidity patterns identi-
fi ed a three-dimensional model underlying these diag-
noses that distinguished an externalizing domain as 
well as an internalizing domain, the latter consisting of 
a panic/phobia dimension and an affective dimension 
including depression and generalized anxiety disorder 
(GAD). (Krueger, 1999; Vollebergh et al. 2001). 
Given the debate about the validity of a categorical 
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distinction between anxiety and depression (Goldberg, 
1996), and the undisputed close relationship between 
both, a long-term study should examine anxiety and 
depression in concert, focusing on comorbidity patterns 
and employing both a dimensional and a categorical 
approach to the diagnosis of depressive and anxiety 
disorders.
Rationale 4: Psychosocial and biological paradigms 
should be integrated when examining depressive and 
anxiety disorders
Studies suggest that depressive and anxiety disorders 
share common risk factors and that similar interven-
tions are effective (Andrews and Stephens, 1990; Brown 
et al., 1996; Beekman et al., 2000). With regard to risk 
factors, there is some evidence supporting the idea that 
depressive and anxiety disorders share longstanding 
vulnerability factors, with recent stress factors deter-
mining the specifi c disorder (Kendler et al., 1987; 
Goldberg and Huxley, 1992). An interdisciplinary 
approach when studying depressive and anxiety disor-
ders is important, since the etiology of these disorders 
is likely multi-causal. Etiological studies have yielded 
important fi ndings, but single risk factors only explain 
modest parts of the etiology. Also for the course of 
disorders, it is unlikely that there exists one single pre-
dictor. Accurate prediction of the course of depressive 
and anxiety disorders requires that psychosocial and 
biological research paradigms be integrated within a 
common psychiatric epidemiological framework 
(Merikangas et al., 2002). The rapid technological 
advances such as genomics have recently allowed such 
integration which enables research into the interaction 
between psychosocial and biological determinants. 
Recent examples confi rm that these domains interact. 
For instance, a serotonin transporter genetic polymor-
phism infl uences depressiveness only when stressful life 
events are present (Caspi et al., 2003), and hypothala-
mic-pituitary-adrenal (HPA) axis dysregulation in 
depression is most obvious after traumatic childhood 
exposure (Heim et al., 2002). These observations have 
indicated that interactions between determinants are 
likely contributing to depressive and anxiety disorders, 
and consequently, may be important as well in deter-
mining their course. Ideally, future psychiatric epide-
miological studies should be designed to integrate 
psychosocial and biological paradigms and should 
be large enough to allow exploration of interaction 
between domains.
Objectives
In line with the rationales mentioned earlier, NESDA 
was designed as a naturalistic, longitudinal cohort 
study including respondents from different health care 
settings (community, primary care and specialized 
mental health care) and in different stages of the devel-
opmental history of disorders (normals, high familial 
risk, subthreshold disorders, fi rst and recurrent epi-
sodes). Depressive and anxiety disorders are studied in 
concert using both dimensional and categorical meas-
urements. Central outcomes and determinants are 
measured in detail at baseline and after one, two, four 
and eight years of follow-up in a cohort of 2981 
adults.
NESDA has three related main study objectives:
(1) Describing the long-term prognosis of depressive 
and anxiety disorders in terms of course (chronic-
ity, recurrence, development of comorbidity, sui-
cidal behaviour) and public health consequences 
(disability, mortality, costs).
(2) Examining clinical, psychosocial, biological and 
genetic determinants of the long-term course and 
consequences of depressive and anxiety disorders.
(3) Examining patient’s expectations, evaluation and 
provision of (mental) health care and their associa-
tion with the long-term course and consequences 
of depressive and anxiety disorders.
It is important to emphasize that NESDA should be 
regarded as an overarching research infrastructure 
intended to foster specifi c research projects to address 
focused research questions and hypotheses. Examples 
of these research projects are, for instance, the exami-
nation of disability patterns among patients with dif-
ferent types of anxiety disorders (part of objective 1), 
the exploration of a gene-environment interaction in 
predicting the chronicity of depression (part of objec-
tive 2), and the examination of received mental health 
care on the course of depressive and anxiety disorders 
(part of objective 3). In addition to these specifi c 
research projects, it is possible to frame some general 
research hypotheses although these can only be based 
on limited (indirect) scientifi c evidence (e.g. Keller 
et al., 1992; Keller, 2006; Bruce et al., 2005). Three 
main examples are: (1) the long-term course of anxiety 
disorders is more chronic than that of depressive dis-
orders, (2) the long-term course of anxiety disorders is 
more homogeneous and therefore infl uenced by a lower 
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number of (diverse) determinants than the course of 
depressive disorders, and (3) comorbidity of anxiety and 
depressive disorders negatively infl uences the long-term 
course and consequences of psychopathology.
In order to judge the interpretation and generaliza-
bility of NESDA fi ndings, it is good to place the Dutch 
mental health care situation in an international per-
spective. First, large-scale epidemiological studies have 
shown that the prevalence of both depression and 
anxiety disorders in the Netherlands is well in the 
range of that in other high income countries such as 
the US, Germany or Canada (Andrade et al., 2003). In 
addition, the structure of the Dutch Health Care 
System is comparable to that of several other European 
countries (e.g. UK, Germany, Italy, Spain) in which the 
general practitioner serves as the gatekeeper and refer-
rals are needed for access to specialized mental health 
care. Results from both the World Health Organization 
(WHO) World Mental Health Surveys and the 
European Study of the Epidemiology of Mental Dis-
orders confi rm that the proportion of diagnosed persons 
receiving mental health treatment as well as the quality 
of care received is well comparable to that in other high 
income countries such as the US, UK, Germany, Spain 
and Belgium (Wang et al., 2007; Alonso et al., 2004). 
Consequently, we have no reason to believe that our 
study results on the long-term course of (treated) 
anxiety or depressive disorders are specifi c to the Dutch 
situation only
NESDA consortium
The NESDA study is largely funded through a special 
grant to stimulate psychiatric research (“Geestkracht”) 
of the Netherlands Scientifi c Organization as well as 
through matching funds from participating universities 
and mental health organizations. A research consor-
tium was established consisting of academic and non-
academic research groups, including the departments 
of psychiatry, general practice and clinical psychology 
of the VU University Medical Centre, the Leiden Uni-
versity Medical Centre and the University Medical 
Centre Groningen, the Centre for Quality of Care 
Research of Radboud University, the Netherlands 
Institute for Health Services Research, and the Neth-
erlands Institute of Mental Health and Addiction. This 
collaboration guarantees access to the diverse expertise 
of a large group of researchers. External (international) 
researchers may collaborate and request access to the 
data.
Methods
Sampling
NESDA has been designed to be representative of those 
with depressive and anxiety disorders in different health 
care settings and stages of the developmental history. 
Therefore, the sample is stratifi ed for setting (commu-
nity, primary care and specialized mental health) and 
set up to include a range of psychopathology: those 
with no symptoms or disorders (‘controls’), those with 
earlier episodes or at risk because of subthreshold symp-
toms or family history, and those with a current fi rst or 
recurrent depressive or anxiety disorder. The Compos-
ite Interview Diagnostic Instrument (CIDI) – lifetime 
version 2.1 – was used to diagnose depressive and 
anxiety disorders according to Diagnostic and Statisti-
cal Manual of Mental Disorders – Fourth Edition 
(DSM-IV) algorithms. The focus is on Dysthymia 
(Dyst), Major Depressive Disorder (MDD), General 
Anxiety Disorder (GAD), Panic Disorder (PAN), Social 
Phobia (SocPhob) and Agoraphobia (AgoraPhob).
Table 1 shows the number of participants recruited 
by setting and developmental stage of illness. Overall, 
807 persons were recruited through mental health care 
organizations, 564 persons through the community 
setting and the remaining 1610 through primary care 
(see later). Across recruitment setting, uniform inclu-
sion and exclusion criteria were used. A general inclu-
sion criterion was an age of 18 through 65 years. In 
order to maintain representativity, only two exclusion 
criteria existed: (1) a primary clinical diagnosis of a 
psychiatric disorder not subject of NESDA which will 
largely affect course trajectory: psychotic disorder, 
obsessive compulsive disorder, bipolar disorder, or severe 
addiction disorder, and (2) not being fl uent in Dutch 
since language problems would harm the validity and 
reliability of collected data.
Recruitment from community samples
The NESDA community sample builds on two cohorts 
that were already available through prior studies.
The fi rst cohort is from the Netherlands Mental 
Health Survey and Incidence Study (NEMESIS), a 
community-based study described in detail elsewhere 
(Bijl et al., 1998). NEMESIS applied a multistage, strati-
fi ed sampling procedure using a random sample of 
private households in 90 Dutch municipalities. The 
adult household member with the most recent birthday 
was asked to participate. A total of 7076 respondents 
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(69.7% of those eligible) participated and were inter-
viewed with the CIDI, version 1.1 in 1996. Follow-up 
interviews were conducted in 1997 (n = 5618) and 1999 
(n = 4796). For NESDA, we included participants with 
a 12-month prevalent depressive (MDD or Dysth) or 
anxiety disorder diagnosis (GAD, SocPhob, Agora-
Phob, PAN) at baseline or a diagnosis during any of the 
two follow-up NEMESIS assessments who did not have 
a CIDI diagnosis of any of the psychiatric diagnoses 
belonging to the exclusion criteria (e.g. psychosis, 
bipolar disorder, obsessive-compulsive disorder). Con-
sequently, a total of 766 NEMESIS participants were 
selected, of whom nine persons had died, eight persons 
had left the Netherlands, and 87 could not be traced 
despite several attempts. Of the 662 persons approached, 
359 (54.2%) refused to participate, none were excluded 
because of language problems, and 303 (45.8%) partici-
pated in NESDA. Those participating did not differ in 
terms of age (p = 0.77), gender (p = 0.79), or type of 
baseline disorder (anxiety, depression or comorbid 
disorder, p = 0.97) from those not participating. An 
important advantage of following this NEMESIS cohort 
within NESDA, is that we have detailed information 
on the prior 10-year history (since 1996) through 
repeated (CIDI) assessments. Of the participating 
303 persons, 104 had a current (six-month) prevalent 
depressive or anxiety disorder at the NESDA baseline 
assessment (see Table 1).
The second cohort exists of participants of the Ado-
lescents at Risk for Anxiety and Depression (ARIADNE) 
study (Landman-Peeters et al., 2005), a prospective 
cohort study among 528 biological children (aged 13–
25 years) of parents who were treated for depressive or 
anxiety disorder as outpatient at a mental health orga-
nization. These children can be considered at high risk 
to develop depressive or anxiety disorders themselves. 
The baseline ARIADNE interview in 2000 consisted 
of a CIDI interview as well as self-report questionnaires. 
Additional follow-up assessments were collected after 
one year (n = 487), two years (n = 458) and four years 
(n = 413). After offi cial closure of the ARIADNE study 
in 2004, 394 participants who were all fl uent in Dutch 
Table 1. Overview of the number of NESDA respondents per recruitment setting
Total 
(N)
N without any 
dep/anx disorder
N with current1 
dep/anx disorder
N with lifetime2 
dep/anx disorder
Recruited from community
Subjects with life-time dep/anx disorder3 303 0 104 303
Subjects with parents with dep/anx 
disorder4
261 138 47 123
Recruited from primary care
Controls: no dep/anx symptoms or 
disorder
373 373 0 0
Subjects with subthreshold symptoms5 141 141 0 0
Subjects with non-current dep/anx 
disorder1
353 0 0 353
Subjects with current dep/anx disorder1 743 0 743 743
Recruited from mental health organizations
Subjects with current dep/anx disorder1 807 0 807 807
Total 2981 652 1701 2329
Note: Dep/anx disorder = depressive or anxiety disorder.
1 Current = six-month prevalence.
2 Lifetime disorders include current diagnoses as well as diagnoses earlier in life.
3 From NEMESIS (see Methods section).
4 From the ARIADNE study (see Methods section).
5 Defi ned as K-10 score ≥ 20 or positive anxiety screening questions or a DSM-diagnosis of minor depression, but not having 
a (prior) history of dep/anx disorder according to the CIDI interview.
Netherlands Study of Depression and Anxiety (NESDA) 127
Int. J. Methods Psychiatr. Res. 17(3): 121–140 (2008)
Copyright © 2008 John Wiley & Sons, Ltd DOI: 10.1002/mpr
and who did not have a CIDI diagnosis of excluding 
psychiatric diagnoses agreed to be contacted for addi-
tional research, of whom one died before contact, 10 
could not be traced, 122 refused, and 261 participated 
in NESDA. The 261 participants were more likely to 
be female (64.0% versus 50.2%, p = 0.001) and have a 
life-time depressive or anxiety disorder (31.0% versus 
22.5%, p = 0.02) compared to the 267 no-participants, 
but no age differences were present (p = 0.43). An 
advantage of including this unique cohort is that 
detailed, prospectively collected data is already availa-
ble for the four years prior to NESDA.
Recruitment from primary care practices
Primary care patients were recruited from 65 general 
practitioners (GPs) in the vicinity of the fi eld sites 
(Amsterdam, Groningen, Leiden). In selecting these 
GPs, attention was paid to the use of an appropriate 
electronic patient record databases which allows 
uniform data extraction for research purposes. This is 
important since collection of GP health care use infor-
mation is part of NESDA, especially to address study 
objective 3.
In the Netherlands, all patients are enlisted at a 
general practice. For the selection of respondents, a 
three-stage screening procedure was used. Screening 
questionnaires were sent to a random sample of 23,750 
patients aged 18–65 years who consulted their GP in 
the last four months irrespective of reason for consulta-
tion. The screening questionnaire consisted of the 
Kessler-10 (K-10; Kessler et al., 2003) with proven 
screening qualities for affective disorders (Furukawa 
et al., 2003; Kessler et al., 2003). Since the K-10 does 
not contain questions for specifi c anxiety disorders, fi ve 
additional questions were added asking for the presence 
(yes/no) of a panic attack, social phobia, agoraphobia, 
general anxiety or nervousness, and psychotropic medi-
cation use during the last month. A screen-positive 
score on the K-10 was defi ned as a validated K-10 score 
of ≥20, (Furukawa et al., 2003) or a positive score on 
any of the added anxiety questions. A total of 10,706 
persons (45%) returned the screener. Those returning 
the screener were more likely to be female (59.3% versus 
50.0%, p < 0.001) and older (44.4 years versus 39.0 years, 
p < 0.001) compared to those not returning the screener. 
Of the screeners returned, 4887 were screen-positive 
(46%) and these persons were approached for a short 
phone-screen interview consisting of the CIDI-
short form sections (MDD, Dysth, GAD, SocPhob, 
Agoraphob, PAN). Those who fulfi lled the CIDI-short 
form criteria for a current depressive or anxiety disorder 
during the phone-screen, and who were not treated for 
psychiatric conditions in a psychiatric mental health 
care setting, were invited to participate in the NESDA 
study. In addition, a random selection of the screen-
negatives (both from the written screener or the phone-
screen) were also invited to participate.
Figure 1 depicts the yield of the three-stage primary 
care screening procedure.A total of 743 participants 
with a current (six-month recency) and 353 participants 
with a non-current depressive or anxiety disorder were 
recruited, as well as 141 persons with subthreshold 
symptoms (screen-positives not fulfi lling diagnostic cri-
teria or a CIDI DSM-IV minor depression diagnosis). 
Finally, 373 participants with a screen-negative score 
and no depressive or anxiety disorder participated and 
constitute a “healthy control group”.
Recruitment from mental health organizations
The specialized mental health patients were recruited 
from outpatient clinics of regional facilities for mental 
health care around the three research sites. For each 
newly enrolled patient at these outpatient clinics, a 
mental health professional conducted a standardized 
intake, which in most, but not all, facilities consisted 
of a structured psychiatric interview [e.g. Mini Interna-
tional Neuropsychiatric Interview (MINI), Structured 
Clinical Interview for DSM-IV (SCID)]. Patients who 
received a primary diagnosis of depressive or anxiety 
disorder, received brief information about NESDA. The 
clinic staff of participating mental health care organiza-
tions submitted 1597 patients with primary depressive 
or anxiety disorder for inclusion. Of these, 87 appeared 
not to fulfi l NESDA inclusion criteria when double-
checked by research staff, 58 could not be reached 
despite multiple efforts, and 39 were excluded due to 
language problems during phone contact. Of the other 
1413 persons contacted by phone, 606 (43%) refused 
participation and 807 (57%) participated in NESDA. 
Those participating were slightly older (38.0 years 
versus 36.5 years, p = 0.04) compared to the 635 who 
refused, but there was no gender difference (p = 0.17).
Characteristics of study sample
The overall sample has a mean age of 41.9 years [stand-
ard deviation (SD) = 13.0] and consists of 1002 men 
(33.6%) and 1979 women (66.4%). The respondents 
have an average of 12.1 years of education (SD = 3.3) 
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and 97% has the Dutch nationality. As shown in 
Table 1, 1701 persons (57.1%) had a current (six-month) 
depressive and/or anxiety disorder, whereas 2329 
persons (78.1%) had a lifetime history. Table 2 illus-
trates that within the sample a total number of 3406 
current and 5446 lifetime depressive and anxiety dis-
orders are present. Especially the current numbers of 
MDD (n = 1115), PAN (n = 670) and SocPhob (n = 665) 
are high. As shown in Table 2, the majority of all cases 
had an age of onset before age 30. Using the Life Chart 
method, more than half of the persons with an anxiety 
disorder and one-third of those with a MDD diagnosis 
reported symptoms during at least 24 out of the 48 
months prior to baseline. At baseline, a total of 748 
(25.1% of the total sample) respondents were using anti-
depressants. Of these 748 respondents, 518 were using 
a selective serotonin reuptake inhibitor (SSRI), 80 were 
using a tricyclic antidepressant (TCA), and 172 were 
using another antidepressant. In addition, 230 respond-
ents were frequently (≥four days a week) using a 
benzodiazepine.
Original sample size calculations were based on the 
examination of course predictors within the smallest 
subgroups of depressive and anxiety disorders. Before-
hand, we calculated that a minimum of 160 persons per 
subgroup were needed to detect a small difference (RR 
Figure 1. Recruitment fl ow of NESDA respondents in the primary care setting. *Current = presence during the 
last six months; non-current = presence before the last six months; subthreshold symptoms are defi ned as screen-
positives or having minor depression according to the CIDI interview.
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= 1.5) in a dichotomous outcome (e.g. yes/no poor 
course with a minimum outcome rate being 25%) given 
a two-sided test, a model including 10 covariates, a 
power of 80% and alpha of 0.05. Table 2 shows that our 
smallest subgroup is 288 (for agoraphobia without panic 
disorder). For many research questions, however, power 
will be larger since analyses will be based on the larger 
disorder groups and on continuous measures.
Measurements
Similar information is collected and similar procedures 
were used for all participants, regardless of recruitment 
setting. The baseline assessment lasted on average four 
hours. Baseline assessments took place at one of the 
seven clinic sites in the three regions around Amster-
dam, Leiden and Groningen. If participants did not 
want to come to the clinic site, they were offered trans-
portation by taxi. A few persons (n = 60) who live far 
away from the fi eld site were offered in-home assess-
ment, for which a van was equipped with all assessment 
tools necessary to conduct the assessment as were it a 
clinic site.
(Mental) health outcomes
Assessment of psychopathology
The NESDA baseline assessment includes various 
indicators of presence, symptomatology, and history of 
depressive and anxiety disorders (see Table 3). The 
diagnoses of depression [minor depression (MinD), 
MDD, Dyst] and anxiety disorders (GAD, SocPhob, 
AgoraPhob, PAN) were established with the CIDI 
(WHO version 2.1) which classifi es diagnoses accord-
ing to the DSM-IV criteria (American Psychiatric 
Association, 2001). The CIDI is used worldwide and 
WHO fi eld research has found high interrater reliabil-
ity (Wittchen et al., 1991), high test–retest reliability, 
(Wacker et al., 2006) and high validity for depressive 
and anxiety disorders (Wittchen et al., 1989; 
Wittchen, 1994). Specially trained clinical research 
staff conducted the CIDI. DSM-IV organic exclusion 
rules were used in making diagnoses, and hierarchy-
free diagnoses were made to allow for research into 
comorbidity. At baseline, the life-time CIDI version 
was used with added questions to determine the 
research DSM-IV diagnosis of current minor depres-
sion (MinD). The life-time CIDI allows for the deter-
mination of the history, recency, duration and age of 
onset of episodes. As has been feasibly used in other 
large-scale studies [Epidemiologic Catchment Area 
(ECA); Eaton et al. 1997] and NEMESIS (Spijker 
et al., 2004), more detailed fl uctuation of depressive 
and anxiety symptoms during the past four years was 
assessed with the Life Chart method. This instrument 
fi rst determines life events in this period to re-fresh 
memory, and then assesses presence and severity of 
symptoms during each quarter of the past four years 
(Lyketsos et al., 1994).
Table 2. Baseline number of depressive or anxiety disorders among the 2981 NESDA respondents
Number of 
Current1 
disorders
Number of 
Lifetime2 
disorders
Percentage 
disorders with 
age of onset 
<30 years
Percentage 
disorders1 
with duration 
>2 years3
Major Depressive Disorder (MDD) 1115 1925 56.7 34.1
Dysthymia3 305 663 55.8 70.3
Panic disorder with/without agoraphobia 670 878 65.4 53.7
Social Phobia 665 908 82.0 51.7
Generalized Anxiety Disorder (GAD) 464 784 53.7 58.1
Agoraphobia without panic disorder 187 288 58.0 58.1
Total number of disorders 3406 5446
1 Current = six-month prevalence.
2 Lifetime disorders include current as well as diagnoses earlier in life.
3 Measured using the Life Chart method and defi ned as reporting symptoms during at least 24 out of the 48 months prior to 
baseline.
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Severity of depressive symptoms was measured with 
the 30-item Inventory of Depressive Symptomatology 
self-report version, which has shown high correlations 
with observer-rated scales and with established respon-
siveness to change (Rush et al., 1996). Although persons 
with depression in the course of a bipolar disorder were 
not included in the study, it was expected that some 
respondents would report manic symptoms, which was 
assessed using the Mood Disorder Questionnaire 
(Hirschfeld et al., 2000). Current suicidality was assessed 
with an interviewer-rated fi ve-item scale of current 
suicide ideation (Beck et al., 1979). Severity of general-
ized anxiety and panic symptoms was measured using 
the 21-item Beck Anxiety Inventory (Beck et al., 1988), 
whereas social and agoraphobia symptoms were meas-
ured using the 15-item Fear Questionnaire (Marks and 
Mathews, 1979).
Given the debate about the validity of categorical 
distinction between anxiety and depression (Goldberg, 
1996) and the undisputed close relationship between 
both, a dimensional approach to diagnosis was also 
considered. A shortened Mood and Anxiety Symptom 
Questionnaire was included, which uses Watson and 
Clarcks tripartite model as the basis (Watson et al., 
1995). This 30-item scale has three subscales consisting 
of lack of positive affect, negative affect and somatic 
anxiety symptoms. Somatization and general distress 
were determined with the validated four-dimensional 
symptoms questionnaire (Terluin et al., 2006). Finally, 
since the prevalence of alcohol use disorders was 
expected to be high, the life-time CIDI-sections for 
alcohol abuse and dependency were administered as 
well as the Audit questionnaire to assess high-risk 
drinking behaviour (Babor et al., 1989).
Assessment of public health consequences
From a patient and public health perspective, the prog-
nosis of mental symptoms should be supplemented with 
information on well-being, functioning, somatic health 
and societal costs. Consequently, validated instruments 
to assess disability (WHO-Disability Assessment 
Schedule II (Chwastiak and von Korff, 2003), and 
disability days (Sheehan et al., 2001), loss of produc-
tivity at work, and health care utilization (TIC-P; 
Hakkaart-van Roijen, 2002) were included (see Table 
3). An inventory of somatic disease was made by 
detailed questions of presence of and receiving treat-
ment for 20 chronic illnesses.
Determinants of (mental) health outcomes
Assessment of demographic and 
personal characteristics
Detailed sociodemographic data were collected, includ-
ing age, sex, ethnicity, place of living, and household 
composition. Socio-economic information was col-
lected by asking for education, occupation and income 
of the respondents and their partner and parents. Per-
sonal history questions included a structured inventory 
of trauma exposure during childhood (emotional 
neglect, psychological abuse, physical abuse, sexual 
abuse and important life-events in early life). The 
Brugha questionnaire (Brugha et al., 1985) assessed 
exposure to 12 important negative events during life 
such as death or serious illness of other family members, 
unemployment and violence experience. Finally, the 
Daily Hassles Questionnaire measures day-to-day expe-
rience of stressful circumstances such as work, private 
or fi nancial problems or arguments (Kanner et al., 
1981).
Psychosocial function
Details about social support from the four most inti-
mate persons is assessed through the social support 
inventory (Stansfeld and Marmot, 1992) and self-report 
questionnaires of loneliness and affi liation are used (de 
Jong-Gierveld and Kamphuis, 1985). The Karasek ques-
tionnaire examines work content and environment 
(Karasek et al., 1998). Personality is operationalized 
using the NEO personality questionnaire, a 60-item 
questionnaire measuring fi ve personality domains: neu-
roticism, extraversion, agreeableness, conscientious-
ness, and openness to experience (Costa and McCrae, 
1995). Locus of control is assessed by a fi ve-item mastery 
scale (Pearlin and Schooler, 1978).
Cognitions have been hypothesized to be important 
as predisposing factors for (a poor course of) depression 
and anxiety disorders. The Leiden index of depression 
sensitivity assesses the extent in which dysfunctional 
cognitions (e.g. rumination, hopelessness, aggression) 
are triggered during normal mood variations (van der 
Does, 2002). The anxiety sensitivity index explores fear 
of anxiety-related somatic sensations (Peterson and 
Reiss, 1992) and the Penn–State Worry Index assesses 
the extent to which persons worry frequently and 
extensively (Meyer et al., 1990). Some relevant (implicit) 
personality constructs are not measurable through 
questionnaires because they operate in an automatic 
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(unconscious) mode that is not accessible to introspec-
tion. Therefore, implicit trait anxiety and depression 
were assessed by means of a modifi ed Implicit Associa-
tion Test (Greenwald et al., 1998) that was designed to 
measure implicit associations between self items on the 
one hand and anxiety-related and depression-related 
items on the other.
Attitude towards health care
The patients’ perspective is essential in any effort to 
reduce long-term effects of disorders. Very little is 
known about the long-term development in relevant 
attitudes, expectations and motivation of patients with 
depressive and anxiety disorders. This is surprising, as 
depression and anxiety are disorders with high levels of 
non-adaptive illness behaviour. NESDA included the 
Quote instrument (Sixma et al., 1998) to measure expe-
rience and evaluation of care for mental health and the 
Perceived Need of Care questionnaire (Meadows et al., 
2000) to assess a person’s care needs.
(Physiological) health indicators
Depressive and anxiety disorders are strongly associated 
to somatic health. To account for these associations 
and to further examine potential underlying biological 
and behavioural mechanisms, NESDA included (physi-
ological) health and health behaviour indicators (Table 
4). The International Physical Activity Questionnaire 
(IPAQ) calculates energy expenditure based on sports 
and other daily activities during a regular day (Craig 
et al., 2003) In addition, sleep behaviour (using the 
Insomnia Rating Scale; Levine et al., 2003), smoking 
behaviour and nicotine dependence (Fagerstrom ques-
tionnaire; Heatherton et al., 1991) and regular drug and 
alcohol use were measured. An inventory of 20 somatic 
conditions was included, and medications used in the 
prior month were registered (by observation of the con-
tainers brought in). Participants who used benzodi-
azepines in the prior month were questioned about 
dependency using the Bendep SRQ (Oude Voshaar et 
al., 2003). Since self-reported disease status may be 
biased by mood, we also included objective, generic 
indicators of health status: a peak fl ow assessment to 
measure lung function capacity and a handgrip strength 
assessment using a hand-held dynanometer. Body com-
position assessment included objective, standardized 
assessments of height, weight and hip and abdominal 
circumference.
Systolic and diastolic blood pressure were measured 
twice in a supine position using an electronic omron 
phygmomanometer. Doppler assessment of ankle and 
arm blood pressure allowed calculation of the ankle/
brachial index, an indicator of peripheral atherosclero-
sis (Newman et al., 1993). Since all baseline assess-
ments took place in the morning, respondents came in 
after an overnight fast. This allowed the draw of a 
fasting sample of 50 millilitres of blood, which were 
immediately transferred to a local laboratory to start 
processing within one hour. Routine assays included 
assessment of hemoglobin, hematocrit, creatinine, 
total, HDL and LDL cholesterol, glucose, triglycerides, 
ASAT, ALAT, gamma-GT, thyroid stimulated hormone 
(TSH) and Free T4. Most of the blood sample, however, 
was processed and stored at −85  °C for later assaying.
Physiological assessment of stress systems
Two important stress systems have been hypothesized 
to be of importance in the adverse health effects of 
depressive and anxiety disorders: the HPA axis and the 
autonomic nervous system. These stress systems may be 
dysregulated and may determine the long-term course 
of depressive or anxiety disorders. Activity of the HPA-
axis was assessed by free cortisol assessment using seven 
saliva samples per respondent. As a measure of a natural 
‘stress’ response of the HPA-axis, the morning cortisol 
awakening response was assessed by taking saliva 
samples at awakening time, 30, 45 and 60 minutes later 
(Wust et al., 2000). To obtain information on basal 
levels and the circadian rhythm, additional saliva 
samples were collected at 22 p.m. and 23 p.m. After-
wards, participants were instructed to ingest 0.5 milli-
grammes of dexamethasone, a specifi c antagonist of the 
glucocorticoid receptor which inhibits adrenocortico-
tropic hormone (ACTH) release at the pituitary gland. 
Immediately after awakening the next morning, the 
extent of cortisol inhibition was determined by a 
seventh saliva sample (Gaab et al., 2002) Respondents 
collected saliva samples on regular (work) days using 
cotton swaps which were returned by mail. After 
receipt, saliva was spun down, stored at −85  °C and 
assayed.
Physiological signals of the autonomic nervous 
system were measured using the ambulatory monitoring 
system (VU-AMS), of which reliability and recording 
methodology have been described previously (de Geus 
et al., 1995). Respondents wore the VU-AMS assess-
ment unobtrusively underneath clothing for two hours 
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Table 4. Collected baseline information on important determinants of (mental) health outcomes in NESDA
Topic Baseline measurement instrument Reference Method
Demographic and personal characteristics
Demographics
 Age, gender, ethnicity Standard questions n/a Int
 Partner + household status Standard questions n/a Int
 Socio-economic status Education, income, occupation n/a Int
Personal history
 Important life events Brugha questionnaire Brugha et al., 1985 Int
 Childhood trauma NEMESIS questionnaire de Graaf et al., 2002 Int
 Daily hassles Daily Hassles questionnaire Kanner et al., 1981 SR
Patient’s perspective
Psychosocial function
 Social support and activity Close Person Inventory Stansfeld et al., 1992 SR
 Work content/environment Karasek questionnaire Karasek et al., 1998 Int
 Loneliness De Jong-Gierveld loneliness scale de Jong-Gierveld and 
Kamphuis, 1985
SR
 Affi liation Van Tilburg scale van Tilburg, 1998 SR
 Personality NEO-FFI questionnaire Costa and McCrae, 1995 SR
 Locus of control Pearlin and Schooler mastery scale Pearlin and Schooler, 1978 SR
 Worry Penn–State Worry Scale Meyer et al., 1990 SR
 Anxiety cognitions Anxiety Sensitivity Index Peterson and Reiss, 1992 SR
 Depression cognitions LEIDS questionnaire van der Does et al., 2002 SR
 Experimental cognitive task Implicit Association Test Greenwald et al., 1998 CT
Health care attitude
 Need of care Perceived Need of Care 
questionnaire
Meadows et al., 2000 Int
 Patient evaluation of care QUOTE questionnaire Sixma et al., 1998 SR 
(Biological) health and genetic measures
Health behaviour
 Regular alcohol intake Drinking behavior questions n/a SR
 Drugs Soft and hard drugs questions n/a SR
 Smoking Past + current smoking questions n/a SR
 Nicotine dependence Fagerstrom questionnaire Heatherton et al., 1991 Int
 Benzodiazepine dependence Bendep SRQ Oude Voshaar et al., 2003 Int
 Physical activity IPAQ questionnaire Craig et al., 2003 SR
(Biological) health markers
 Presence of 20 diseases Standard self-report questions + 
GP data
n/a Int, GP
 Pain Chronic graded pain scale von Korff, 1992 Int
 Sleep Insomnia Rating Scale Levine et al., 2003 SR
 Pulmonary function Peak fl ow measurement n/a ME
 Muscle strength Grip strength assessment n/a ME
 Biomarkers Fasting blood sample n/a Blood
 Body composition Weight, height, waist + hip 
circumference
n/a ME
 Blood pressure (BP) Systolic and diastolic BP 
assessment 
n/a ME
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 Peripheral atherosclerosis Doppler assessment of ankle-arm 
index
n/a ME
 Autonomic nervous system Electro + impedance cardiography de Geus et al., 1995 ME
 HPA-axis (salivary cortisol) Seven saliva samples, including 
DST test
n/a Saliva 
Genetic measures
 Family history Family tree inventory Fyer and Weissman, 1999 Int
 DNA/lymphocytes Full blood Boomsma et al., 2008 Blood
Proteomics Serum Boomsma et al., 2008 Blood
Gene-expression (RNA) Before + after LPS-challenge Boomsma et al., 2008 Blood 
Note: SR = self-report; Int = interview; GP = data collection through general practitioner records; Blood = data collection via 
fasting blood sample; CT = computer task; ME = medical examination.
Table 4. continued
Topic Baseline measurement instrument Reference Method
during which continuous time series of R wave-to-R 
wave intervals and respiration rates were registered 
from a three-lead electrocardiogram and a four-lead 
impedance cardiogram. From these, valid indicators 
(e.g. heart rate variability, pre-ejection period, respira-
tion sinus arrhythmia) of parasympathetic and sympa-
thetic cardiac activity were obtained.
Genetic determinants
Depressive and anxiety disorders are highly heritable, 
with heritability estimates between 35–40% (Sullivan 
et al., 2000). Consequently, it is likely that underlying 
genetic factors (in interaction with environmental 
factors) determine the onset and course of depressive 
and anxiety disorders. NESDA is therefore set up to 
provide genetic indicators for future genetic research. 
Briefl y, for all participants DNA was isolated from the 
baseline blood sample. Through funding from the 
fNIH GAIN programme (www.fnih.gov/gain), whole 
genome scan analysis were conducted for 1860 NESDA 
participants to be compared with 1860 controls from 
the Netherlands Twin Registry (see for more details: 
Boomsma et al., 2008). For all respondents, lymphocytes 
were stored so that future genomic information 
can be obtained. In addition, to examine the genome 
responsiveness at the individual genetic background of 
individuals, we also set up samples for later gene-
expression profi ling and proteomics. For this purpose, 
we stored one heparin tube with blood at −80  °C, and 
stored another heparin tube after a lipopolysacharride 
(LPS) challenge had been added and incubated for fi ve 
hours. After future micro array analyses, gene-
expression profi ling in unchallenged and challenged 
samples can for instance be compared between 
depressed or anxious patients and controls. Finally, 
family history of depressive and anxiety disorders is 
explored using the family tree method (Fyer and 
Weissman, 1999).
Additional data collection
Functional magnetic resonance imaging (fMRI)
Although several functional magnetic resonance 
imaging (fMRI) studies have now confi rmed neurobio-
logical abnormalities among depression and anxiety 
patients (Anand and Shekhar, 2003; Deckersbach 
et al., 2006), the specifi city of these abnormalities, and 
associations with e.g. severity and duration have not 
been fully explored. Also the prognostic importance of 
(change in) neurobiological parameters for the course 
of depression and anxiety disorders remains largely 
unknown, which is the main reason for including fMRI 
assessments in a subgroup of the NESDA cohort. Both 
volumetric and functional MRI using a 3 Tesla MRI 
scanner was performed in fi ve subgroups (total n = 301): 
controls (n = 69), and current (one-month recency) 
cases with MDD (n = 94), social phobia (n = 28), panic 
disorder (n = 26) and in cases with multiple disorders 
(n = 88). Included paradigms are the Eckman Faces task 
(Canli et al., 2005), the Tower of London planning task 
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(van den Heuvel et al., 2003) and an episodic memory 
task of encoding and retrieval (Daselaar et al., 2003). 
fMRI assessments will be repeated two and four years 
after baseline.
Information from GPs
For respondents recruited in primary care, additional 
data from GPs were collected. Participating GPs fi lled 
out a questionnaire about practice characteristics and 
their medical experience and attitude towards (mental) 
health care. In addition, the GP’s electronic patient 
register data were extracted during the NESDA follow-
up period. This data extraction includes information 
on medical history, number of and reasons for GP visits, 
prescribed medication, and referrals starting from the 
year prior to baseline. This will be used for e.g. data 
verifi cation of health care utilization and health care 
costs. Since the charging to the insurance company is 
connected with completion of the electronic patient 
record, this information is rather complete. The con-
sequent coding of somatic, social and psychiatric diag-
noses in electronic patient records provides reliable 
information on daily care (Okkes et al., 2002).
Procedures
In the baseline assessment, the use of a laptop computer 
was central. Interviews were administered with compu-
ter-assisted personalized interviewing procedures with 
data entry checks on outliers and routing. All inter-
views were taped to monitor data-quality and inter-
viewer performance. When the assessment was 
completed, respondents were compensated with a small 
incentive (gift certifi cate of 15 euro and payment of 
travel costs) for their time and cooperation.
Staff training and supervision
In order to conduct the study, more than 40 research 
assistants have been trained. The majority of research 
assistants consisted of psychologists, nurses or residents 
in psychiatry. Research assistants received one week of 
training by the fi eldwork coordinator. A research assist-
ant was certifi ed to conduct assessments after approval 
of audiotapes of at least two complete interviews. Ques-
tion wording and probing behaviour of interviewers was 
constantly monitored by checking a random selection 
of about 10% of all taped interviews. In addition, a 
continuous monitoring system of interviewer variances 
and interviewer specifi c item-non response was main-
tained through computer analyses in SPSS.
Data management and control
The NESDA coordinating centre at the Department of 
Psychiatry of the VU University Medical Centre serves 
as data monitoring centre. The data management team 
focuses on data archiving, checking of data errors, crea-
tion of (summary) variables and scales, and maintain-
ing and updating central data bases. Electronic data 
from the interviews were sent on a weekly basis to the 
coordinating centre, where data were entered in central 
databases. Data quality checks were routinely carried 
out to review missing data and check for 
inconsistencies.
Ethical issues
The study protocol was approved centrally by the 
Ethical Review Board of the VU University Medical 
Centre and subsequently by local review boards of each 
participating centre. After full verbal and written 
information about the study, written informed consent 
was obtained from all participants at the start of base-
line assessment. This written informed consent asked 
for permission to use genetic information, to retrieve 
health care information from physicians, and to link 
respondent information to external data banks (e.g. 
mortality or hospitalization databases). Confi dentiality 
of data is maintained by using a unique research ID 
number for each respondent, which enables to identify 
individuals without using names. Only a limited number 
of persons (principal investigator, data manager) have 
access to the record that link ID number to identifi able 
information.
Time line and follow-up assessments
Recruitment of the NESDA sample started in Septem-
ber 2004 and was completed in February 2007. In 
September 2005 and September 2006, the one-year and 
two-year follow-up assessments started. The one-year 
follow-up assessment consists of a written questionnaire 
containing the most important self-report instruments 
to determine demographic changes, recent life events 
and the course and consequences of anxiety and depres-
sion symptoms. The two-year follow-up assessment con-
sists of a face-to-face clinic visit, in which baseline 
assessments – except those concerning stable concepts 
– are repeated. A few additional assessments were 
included: the CIDI bipolar disorder section, questions 
about experienced side effects and effectiveness 
of used psychotropic medication, a computerized 
working memory task (N-back; Carlson et al., 1998), 
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a computerized exogeneous cueing task (Koster et al., 
2005) to assess attentional bias for depression and 
anxiety, and an index of seasonality of symptoms 
(Seasonal Pattern Assessment Questionnaire; Mersch 
et al. 2004). The four-year and eight-year follow-up 
assessments will start in September 2008 and 2012, 
respectively.
Conclusion
NESDA is multisite, longitudinal, naturalistic cohort 
study examining the eight-year course and consequen-
ces of depressive and anxiety disorders. Although psy-
chiatric epidemiology has provided us insight into the 
high prevalence of depressive and anxiety disorders and 
their large impact on public health, there is relatively 
much less known about the long-term course of these 
disorders and its determinants. NESDA’s large sample 
size and detailed assessment of both mental health out-
comes and determinants. In sum, NESDA provides a 
unique opportunity to learn more about the prognosis 
of two of the most common and burdensome disorders 
for society. Better prediction of prognosis will allow 
more accurate and effi cient planning of the limited 
health care resources and thereby ultimately contribute 
to health improvement of patients with depressive and 
anxiety disorders.
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